Chemed Yönetim

Yönetim kriter kontrolleri 3/4

Chemed CEO'su Kevin McNamara, Aug1994 tarihinde atandı, in görev süresi 30.25 yıldır. in toplam yıllık tazminatı $ 12.63M olup, şirket hissesi ve opsiyonları dahil olmak üzere 12.7% maaş ve 87.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.69% ine doğrudan sahiptir ve bu hisseler $ 55.15M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 24.5 yıl ve 15.5 yıldır.

Anahtar bilgiler

Kevin McNamara

İcra Kurulu Başkanı

US$12.6m

Toplam tazminat

CEO maaş yüzdesi	12.7%
CEO görev süresi	30.3yrs
CEO sahipliği	0.7%
Yönetim ortalama görev süresi	24.5yrs
Yönetim Kurulu ortalama görev süresi	15.5yrs

Son yönetim güncellemeleri

Recent updates

The Chemed Corporation (NYSE:CHE) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Nov 01

Chemed Corporation's (NYSE:CHE) Business Is Yet to Catch Up With Its Share Price

Oct 29

Here's Why Chemed Corporation's (NYSE:CHE) CEO Compensation Is The Least Of Shareholders' Concerns

May 14

Is Chemed Corporation (NYSE:CHE) Trading At A 50% Discount?

Apr 26

Chemed Corporation (NYSE:CHE) Full-Year Results: Here's What Analysts Are Forecasting For This Year

Mar 01

The Price Is Right For Chemed Corporation (NYSE:CHE)

Dec 30

Chemed: Continues To Compound Shareholder Value At Double-Digit Returns

Nov 30

Chemed (NYSE:CHE) Is Aiming To Keep Up Its Impressive Returns

Oct 26

Chemed - Showcasing Why It's So Reliable

Aug 26

Chemed: Still Bullish On Economic Characteristics, But Risks Shouldn't Be Overlooked

Aug 13

Is Chemed Corporation (NYSE:CHE) Worth US$521 Based On Its Intrinsic Value?

Aug 01

Capital Investments At Chemed (NYSE:CHE) Point To A Promising Future

Jul 14

Chemed (NYSE:CHE) Has A Rock Solid Balance Sheet

Jun 07

Chemed (NYSE:CHE) Is Aiming To Keep Up Its Impressive Returns

Apr 09

Chemed Q4 2022 Earnings Preview

Feb 22

Chemed Corporation: Long-Term Tailwinds, But Remains A Hold

Feb 14

Is Chemed (NYSE:CHE) Using Too Much Debt?

Jan 05

Here's What Chemed's (NYSE:CHE) Strong Returns On Capital Mean

Dec 17

Chemed declares $0.38 dividend

Nov 04

Chemed Q3 2022 Earnings Preview

Oct 28

Does Chemed (NYSE:CHE) Have A Healthy Balance Sheet?

Oct 01

Capital Investment Trends At Chemed (NYSE:CHE) Look Strong

Sep 16

CEO Tazminat Analizi

Kevin McNamara'un ücretlendirmesi Chemed'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$302m
Jun 30 2024	n/a	n/a	US$301m
Mar 31 2024	n/a	n/a	US$283m
Dec 31 2023	US$13m	US$2m	US$273m
Sep 30 2023	n/a	n/a	US$245m
Jun 30 2023	n/a	n/a	US$226m
Mar 31 2023	n/a	n/a	US$240m
Dec 31 2022	US$12m	US$1m	US$250m
Sep 30 2022	n/a	n/a	US$262m
Jun 30 2022	n/a	n/a	US$277m
Mar 31 2022	n/a	n/a	US$267m
Dec 31 2021	US$12m	US$1m	US$269m
Sep 30 2021	n/a	n/a	US$308m
Jun 30 2021	n/a	n/a	US$303m
Mar 31 2021	n/a	n/a	US$329m
Dec 31 2020	US$12m	US$1m	US$319m
Sep 30 2020	n/a	n/a	US$271m
Jun 30 2020	n/a	n/a	US$263m
Mar 31 2020	n/a	n/a	US$231m
Dec 31 2019	US$10m	US$1m	US$220m
Sep 30 2019	n/a	n/a	US$209m
Jun 30 2019	n/a	n/a	US$201m
Mar 31 2019	n/a	n/a	US$205m
Dec 31 2018	US$9m	US$1m	US$206m
Sep 30 2018	n/a	n/a	US$206m
Jun 30 2018	n/a	n/a	US$190m
Mar 31 2018	n/a	n/a	US$113m
Dec 31 2017	US$8m	US$1m	US$98m

Tazminat ve Piyasa: Kevin 'nin toplam tazminatı ($USD 12.63M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 8.06M ).

Tazminat ve Kazançlar: Kevin 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Kevin McNamara (70 yo)

30.3yrs

Görev süresi

US$12,625,106

Tazminat

Mr. Kevin J. McNamara has been the Chief Executive Officer of Chemed Corporation since May 2001 and has been its President since August 2, 1994. Previously, Mr. McNamara served as an Executive Vice Preside...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kevin McNamara	CEO, President & Director	30.3yrs	US$12.63m	0.69% $ 55.2m
Michael Witzeman	VP, Controller	12.5yrs	US$2.93m	0.025% $ 2.0m
Spencer Lee	Executive Vice President	24.5yrs	US$3.37m	0.13% $ 10.6m
Thomas Hutton	VP & Director	36.8yrs	Veri yok	0.56% $ 44.6m
Nicholas Westfall	Executive Vice President	8.4yrs	US$4.71m	0.041% $ 3.2m
Lisa Reinhard	VP, Chief Administrative Officer & Secretary	30yrs	Veri yok	Veri yok
Sherri Warner	Director of Investor Relations	no data	Veri yok	Veri yok
Brian Judkins	VP, Secretary & Chief Legal Officer	4.3yrs	Veri yok	0.0095% $ 756.4k
Nathan McNamara	VP & Chief Strategy Officer	no data	Veri yok	Veri yok

24.5yrs

Ortalama Görev Süresi

52.5yo

Ortalama Yaş

Deneyimli Yönetim: CHE 'un yönetim ekibi deneyimli ve deneyimlidir ( 24.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kevin McNamara	CEO, President & Director	37.8yrs	US$12.63m	0.69% $ 55.2m
Thomas Hutton	VP & Director	39.8yrs	Veri yok	0.56% $ 44.6m
Thomas Rice	Independent Director	15.5yrs	US$278.27k	0.040% $ 3.2m
Sandra Laney	Director Emeritus	15.5yrs	US$157.02k	Veri yok
Patrick Grace	Independent Director	28.8yrs	US$308.60k	0.022% $ 1.7m
George Walsh	Independent Chairman	29.8yrs	US$453.15k	0.023% $ 1.9m
Andrea Lindell	Independent Director	16.5yrs	US$272.77k	0.038% $ 3.0m
Christopher Heaney	Independent Director	4.5yrs	US$279.43k	0.014% $ 1.1m
Ron DeLyons	Independent Director	4.5yrs	US$278.27k	0.0093% $ 738.1k
John Mount	Independent Director	2.3yrs	US$278.27k	0.0044% $ 346.8k
Eileen McCarthy	Independent Director	1.5yrs	US$238.52k	0.0039% $ 307.2k

15.5yrs

Ortalama Görev Süresi

70yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CHE 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 15.5 yıldır).

Chemed Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

CEO, President & Director recently sold US$1.2m worth of stock

Executive Vice President recently sold US$975k worth of stock

Executive Vice President exercised options and sold US$1.6m worth of stock

VP & Director notifies of intention to sell stock

Executive Vice President recently sold US$1.1m worth of stock

Executive Vice President notifies of intention to sell stock

Recent updates

The Chemed Corporation (NYSE:CHE) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Third quarter 2024 earnings: EPS misses analyst expectations

Now 29% undervalued after recent price drop

Chemed Corporation Revises Consolidated Earnings Guidance for the Full Year 2024

Chemed Corporation's (NYSE:CHE) Business Is Yet to Catch Up With Its Share Price

CEO, President & Director recently sold US$1.2m worth of stock

Chemed Corporation to Report Q3, 2024 Results on Oct 29, 2024

Executive Vice President recently sold US$975k worth of stock

Executive Vice President exercised options and sold US$1.6m worth of stock

Capital Investments At Chemed (NYSE:CHE) Point To A Promising Future

Chemed Remains A Buy On Long-Term Economics

VP & Director notifies of intention to sell stock

Second quarter dividend increased to US$0.50

Chemed Corporation Declares Quarterly Dividend, Payable on August 30, 2024

Executive Vice President recently sold US$1.1m worth of stock

Executive Vice President notifies of intention to sell stock

Second quarter 2024 earnings: EPS misses analyst expectations

Chemed Corporation's (NYSE:CHE) Shares May Have Run Too Fast Too Soon

Chemed Corporation to Report Q2, 2024 Results on Jul 24, 2024

CEO, President & Director recently sold US$816k worth of stock

CEO, President & Director notifies of intention to sell stock

First quarter dividend of US$0.40 announced

Chemed Corporation Declares Quarterly Dividend, Payable on June 18, 2024

Chemed: Growth Does Not Justify The Current Stock Price

CEO, President & Director recently sold US$2.3m worth of stock

Here's Why Chemed Corporation's (NYSE:CHE) CEO Compensation Is The Least Of Shareholders' Concerns

Is Chemed Corporation (NYSE:CHE) Trading At A 50% Discount?

Chemed Corporation Reiterates Earnings Guidance for Full Year 2024

First quarter 2024 earnings: EPS misses analyst expectations

Chemed Corporation, Annual General Meeting, May 20, 2024

New major risk - Revenue and earnings growth

Executive Vice President exercised options and sold US$3.8m worth of stock

Executive Vice President recently sold US$1.3m worth of stock

Chemed Corporation to Report Q1, 2024 Results on Apr 24, 2024

Price target increased by 10% to US$690

Chemed Corporation (NYSE:CHE) Full-Year Results: Here's What Analysts Are Forecasting For This Year

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Now 22% overvalued after recent price rise

Third quarter dividend of US$0.40 announced

Chemed Corporation Declares Quarterly Dividend, Payable on March 15, 2024

Chemed Corporation to Report Q4, 2023 Results on Feb 27, 2024

The Price Is Right For Chemed Corporation (NYSE:CHE)

Chemed Corporation Appoints Michael D. Witzeman as Chief Financial Officer, Effective January 1, 2024

CEO, President & Director recently sold US$859k worth of stock

Chemed: Continues To Compound Shareholder Value At Double-Digit Returns

Executive Vice President recently sold US$580k worth of stock

Executive VP & CFO notifies of intention to sell stock

Chemed Corporation Announces the Retirement of David P. Williams as Chief Financial Officer Effective December 31, 2023

Chemed Corporation Announces the Retirement of David P. Williams as Chief Financial Officer Effective December 31, 2023

Executive VP & CFO exercised options to buy US$5.9m worth of stock.

CEO, President & Director recently sold US$1.7m worth of stock

Chemed Corporation Provides Earnings Guidance for the Full-Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Chemed (NYSE:CHE) Is Aiming To Keep Up Its Impressive Returns

Chemed Corporation to Report Q3, 2023 Results on Oct 25, 2023

Chemed - Showcasing Why It's So Reliable

Chemed: Still Bullish On Economic Characteristics, But Risks Shouldn't Be Overlooked

CEO, President & Director recently sold US$2.1m worth of stock

Is Chemed Corporation (NYSE:CHE) Worth US$521 Based On Its Intrinsic Value?

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Capital Investments At Chemed (NYSE:CHE) Point To A Promising Future

Chemed Corporation to Report Q2, 2023 Results on Jul 26, 2023

Chemed (NYSE:CHE) Has A Rock Solid Balance Sheet

Executive Vice President notifies of intention to sell stock

Independent Director recently sold US$160k worth of stock

Independent Director notifies of intention to sell stock

CEO, President & Director recently sold US$2.2m worth of stock

CEO, President & Director exercised options and sold US$412k worth of stock

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind